阿斯利康的双检查点抑制剂STRIDE方案获批治疗无手术指征的肝细胞肝癌(HCC)!双检查点:抗CTLA-4单抗Imjudo(tremelimumab)和抗PD-L1单抗Imfinzi(durvalumab),STRIDE方案:单一剂抗CTLA-4抗体Imjudo 300mg,外加常规每4周1500mg的Imfinzi(Single Tremelimumab Regular Interval Durvalumab);批 ...